The Gulf Cooperation Council (GCC) region has a population of 59 million and a strong focus on developing its healthcare infrastructure and services, making it a significant region of interest for pharma and biotech companies. Economic growth, investment in technology, and a strong emphasis on local pharmaceutical development have facilitated recent growth in the sector. This growth is expected to continue for several years, indicating that now is a prime time for foreign companies to consider focusing and investing in the region, particularly the region leader, Saudi Arabia.